Literature DB >> 24621116

Associations of hemodynamic load and ventricular repolarization in patients with newly diagnosed essential hypertension: a long-term follow-up study.

Velissaris Antonakis, Costas Tsioufis, Dimitris Tsiachris, Ioannis Andrikou, Maria Fantaki, Nikos Dagres, Nikos Vrachnis, Christodoulos Stefanadis.   

Abstract

The evolution of QT interval and its dispersion (QTd) were studied in 135 newly diagnosed nondiabetic patients, as well as the relationship between changes of these left ventricular (LV) repolarization parameters with blood pressure (BP) and LV mass changes, which were prospectively studied for a median period of 3.8 years. At baseline and at last follow-up visit, all patients underwent ambulatory BP monitoring, echocardiographic assessment, and 12-lead electrocardiography. At the end of follow-up, responders of antihypertensive treatment based on a reduced 24-hour systolic BP (n=122) exhibited a reduction in LV mass index (by 7.6 g/m2, P<.001) and corrected QT (by 4.3, P=.038), while corrected QTd was unchanged. In nonresponders (n=13), although no difference in LV mass index was observed, corrected QT increased by 12.4 ms (P=.048) and corrected QTd by 8.2 ms (P=.027). Changes in parameters of LV repolarization were related to BP changes but not to changes of myocardial size.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24621116      PMCID: PMC8031782          DOI: 10.1111/jch.12275

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

1.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

2.  Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril.

Authors:  J R González-Juanatey; J M García-Acuña; A Pose; A Varela; C Calvo; J Cabezas-Cerrato; M G de la Peña
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

3.  Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction.

Authors:  L Oikarinen; M S Nieminen; M Viitasalo; L Toivonen; K Wachtell; V Papademetriou; S Jern; B Dahlöf; R B Devereux; P M Okin
Journal:  J Hypertens       Date:  2001-10       Impact factor: 4.844

4.  Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.

Authors:  Yasunari Matsuno; Shinya Minatoguchi; Hisayoshi Fujiwara
Journal:  Blood Press Suppl       Date:  2011-01-19

5.  Irbesartan reduces QT dispersion in hypertensive individuals.

Authors:  P O Lim; M Nys; A A Naas; A D Struthers; M Osbakken; T M MacDonald
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

6.  Prolonged QT interval at onset of acute myocardial infarction in predicting early phase ventricular tachycardia.

Authors:  G J Taylor; R S Crampton; R S Gibson; P T Stebbins; M T Waldman; G A Beller
Journal:  Am Heart J       Date:  1981-07       Impact factor: 4.749

7.  Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.

Authors:  Lasse Oikarinen; Markku S Nieminen; Lauri Toivonen; Matti Viitasalo; Kristian Wachtell; Vasilios Papademetriou; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin
Journal:  Am Heart J       Date:  2003-05       Impact factor: 4.749

8.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jose Luis Zamorano; Sverre E Kjeldsen; Serap Erdine; Krzysztof Narkiewicz; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Renata Cifkova; Anna Dominiczak; Robert Fagard; Anthony M Heagerty; Stephane Laurent; Lars H Lindholm; Giuseppe Mancia; Athanasios Manolis; Peter M Nilsson; Josep Redon; Roland E Schmieder; Harry A J Struijker-Boudier; Margus Viigimaa; Gerasimos Filippatos; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Wolfgang Kiowski; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Margus Viigimaa; Bernard Waeber; Bryan Williams; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2007-06-11       Impact factor: 29.983

9.  Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension.

Authors:  E A Karpanou; G P Vyssoulis; A Psichogios; C Malakou; E A Kyrozi; D V Cokkinos; P K Toutouzas
Journal:  Am Heart J       Date:  1998-11       Impact factor: 4.749

10.  QT dispersion and sudden unexpected death in chronic heart failure.

Authors:  C S Barr; A Naas; M Freeman; C C Lang; A D Struthers
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321

View more
  1 in total

Review 1.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.